GB9911823D0 - New vaccine formulations - Google Patents

New vaccine formulations

Info

Publication number
GB9911823D0
GB9911823D0 GBGB9911823.4A GB9911823A GB9911823D0 GB 9911823 D0 GB9911823 D0 GB 9911823D0 GB 9911823 A GB9911823 A GB 9911823A GB 9911823 D0 GB9911823 D0 GB 9911823D0
Authority
GB
United Kingdom
Prior art keywords
vaccine formulations
new vaccine
new
formulations
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9911823.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyvax Ltd
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Priority to GBGB9911823.4A priority Critical patent/GB9911823D0/en
Publication of GB9911823D0 publication Critical patent/GB9911823D0/en
Priority to AT00931400T priority patent/ATE259655T1/de
Priority to AU49356/00A priority patent/AU4935600A/en
Priority to JP2000619457A priority patent/JP2003500366A/ja
Priority to EP00935287A priority patent/EP1178823A2/fr
Priority to PCT/GB2000/001918 priority patent/WO2000071155A2/fr
Priority to AU50843/00A priority patent/AU5084300A/en
Priority to EP00931400A priority patent/EP1178822B1/fr
Priority to PCT/GB2000/001921 priority patent/WO2000071156A2/fr
Priority to PCT/GB2000/001938 priority patent/WO2000071157A2/fr
Priority to KR1020017014806A priority patent/KR20020027318A/ko
Priority to AU49357/00A priority patent/AU4935700A/en
Priority to DE60008368T priority patent/DE60008368T2/de
Priority to ES00931400T priority patent/ES2215662T3/es
Priority to CA002374294A priority patent/CA2374294A1/fr
Priority to CA002373730A priority patent/CA2373730A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB9911823.4A 1999-05-21 1999-05-21 New vaccine formulations Ceased GB9911823D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB9911823.4A GB9911823D0 (en) 1999-05-21 1999-05-21 New vaccine formulations
CA002373730A CA2373730A1 (fr) 1999-05-21 2000-05-19 Nouvelles preparations vaccinales - 1
AU50843/00A AU5084300A (en) 1999-05-21 2000-05-19 New vaccine formulations - 1
PCT/GB2000/001921 WO2000071156A2 (fr) 1999-05-21 2000-05-19 Nouvelles formulations vaccinales-3
JP2000619457A JP2003500366A (ja) 1999-05-21 2000-05-19 新規ワクチン製剤２
EP00935287A EP1178823A2 (fr) 1999-05-21 2000-05-19 Nouvelles preparations vaccinales - 1
PCT/GB2000/001918 WO2000071155A2 (fr) 1999-05-21 2000-05-19 Nouvelles formulations vaccinales -2
AT00931400T ATE259655T1 (de) 1999-05-21 2000-05-19 Aus ganzen zellen bestehender krebs-impfstoff, enthaltend ko-kultivierte maligne und nicht- maligne zellen
EP00931400A EP1178822B1 (fr) 1999-05-21 2000-05-19 Vaccin anticancereux a cellules entieres comprenant des cellules malignes et non-malignes co-cultivees
AU49356/00A AU4935600A (en) 1999-05-21 2000-05-19 New vaccine formulations - 2
PCT/GB2000/001938 WO2000071157A2 (fr) 1999-05-21 2000-05-19 Nouvelles preparations vaccinales - 1
KR1020017014806A KR20020027318A (ko) 1999-05-21 2000-05-19 신규 백신 제제-2
AU49357/00A AU4935700A (en) 1999-05-21 2000-05-19 New vaccine formulations-3
DE60008368T DE60008368T2 (de) 1999-05-21 2000-05-19 Aus ganzen zellen bestehender krebs-impfstoff, enthaltend ko-kultivierte maligne und nicht-maligne zellen
ES00931400T ES2215662T3 (es) 1999-05-21 2000-05-19 Vacuna de celulas enteras para el cancer que contiene celulas malignas y no malignas co-cultivadas.
CA002374294A CA2374294A1 (fr) 1999-05-21 2000-05-19 Nouvelles formulations vaccinales -2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9911823.4A GB9911823D0 (en) 1999-05-21 1999-05-21 New vaccine formulations

Publications (1)

Publication Number Publication Date
GB9911823D0 true GB9911823D0 (en) 1999-07-21

Family

ID=10853879

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9911823.4A Ceased GB9911823D0 (en) 1999-05-21 1999-05-21 New vaccine formulations

Country Status (5)

Country Link
EP (1) EP1178823A2 (fr)
AU (1) AU5084300A (fr)
CA (1) CA2373730A1 (fr)
GB (1) GB9911823D0 (fr)
WO (1) WO2000071157A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293212A1 (fr) * 2001-08-21 2003-03-19 National Research Council Of Canada Vaccin contre le cancer comprenant des cellules cancéreuses entières ayant un acide sialique modifié
EP2710037B1 (fr) * 2011-05-19 2019-07-31 The Regents of The University of Michigan Agents se liant à l'intégrine alpha-2 et leur utilisation pour inhiber la prolifération des cellules cancéreuses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69627527T2 (de) * 1995-12-28 2004-03-04 The Johns Hopkins University School Of Medicine Allogene parakrine cytokine tumor impfstoffe
ATE239781T1 (de) * 1996-02-02 2003-05-15 Us Gov Health & Human Serv Immortalisierte menschliche prostata- epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
US5804443A (en) * 1997-02-28 1998-09-08 Bernofsky; Carl Human monocytic leukemia cell line

Also Published As

Publication number Publication date
CA2373730A1 (fr) 2000-11-30
EP1178823A2 (fr) 2002-02-13
WO2000071157A2 (fr) 2000-11-30
WO2000071157A3 (fr) 2001-04-12
AU5084300A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
PL392363A1 (pl) Kompozycja szczepionki
IL145044A0 (en) Vaccine
HUS1300072I1 (hu) Vakcina
GB9910812D0 (en) Vaccine composition
GB9915204D0 (en) Vaccine
GB9906437D0 (en) Vaccine
GB9913327D0 (en) Vaccine
GB9911823D0 (en) New vaccine formulations
GB9911825D0 (en) New vaccine formulations
GB9911824D0 (en) New vaccine formulations
GB9909072D0 (en) Vaccine
GB9922700D0 (en) Vaccine
GB0008029D0 (en) New vaccine formulations
GB9925619D0 (en) Vaccine
GB9919260D0 (en) Vaccine
GB9904408D0 (en) Vaccine
GB9904412D0 (en) Vaccine
GB9905511D0 (en) Vaccine
GB9927336D0 (en) Vaccine
GB9918647D0 (en) Vaccine
GB9904405D0 (en) Vaccine
GB9915106D0 (en) Vaccine
GB9915205D0 (en) Vaccine
GB9916677D0 (en) Vaccine
GB9925618D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)